Literature DB >> 8562503

Evidence for invariant chain 85-101 (CLIP) binding in the antigen binding site of MHC class II molecules.

N Bangia1, T H Watts.   

Abstract

The region of invariant chain encompassing residues 81-104 is critical for association with MHC class II molecules. This segment of invariant chain, termed CLIP for Class II-associated invariant chain Peptides, has been shown to inhibit antigenic peptide binding and T cell stimulation. Polymorphism affects the ability of CLIP to inhibit antigenic peptide binding, suggesting that CLIP may occupy the MHC II antigen binding site directly. However, CLIP may also mediate inhibition by binding to an alternate site causing an allosteric change to prevent antigenic peptide binding. The relationship between the apparent dissociation constant in the presence of a competitor (Kapp) and the competitor concentration can be examined to determine the nature of competition between two ligands. In competitive binding experiments between CLIP and antigenic peptide we find a linear dependence of Kapp on competitor concentration. These data are consistent with CLIP and antigenic peptide competing for the same site on the MHC class II molecule, thus arguing against an allosteric mechanism of CLIP inhibition. Mildly acidic conditions are thought to promote peptide loading in the endosome compartment by facilitating CLIP dissociation and enhancing antigenic peptide association. We have compared the effect of acidic pH on the equilibrium binding of murine CLIP and antigenic peptide to MHC class II molecules. Like antigenic peptide, CLIP binding can be greatly enhanced at mildly acidic pH, suggesting that a passive competitive mechanism for CLIP removal may not be sufficient to achieve loading of antigenic peptide in the endosome.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8562503     DOI: 10.1093/intimm/7.10.1585

Source DB:  PubMed          Journal:  Int Immunol        ISSN: 0953-8178            Impact factor:   4.823


  6 in total

Review 1.  HLA-DM and the MHC class II antigen presentation pathway.

Authors:  P E Jensen; D A Weber; W P Thayer; X Chen; C T Dao
Journal:  Immunol Res       Date:  1999       Impact factor: 2.829

2.  Distinct antigen MHC class II complexes generated by separate processing pathways.

Authors:  R Lindner; E R Unanue
Journal:  EMBO J       Date:  1996-12-16       Impact factor: 11.598

3.  Energetic asymmetry among hydrogen bonds in MHC class II*peptide complexes.

Authors:  B J McFarland; J F Katz; C Beeson; A J Sant
Journal:  Proc Natl Acad Sci U S A       Date:  2001-07-24       Impact factor: 11.205

4.  Impact of negatively charged patches on the surface of MHC class II antigen-presenting proteins on risk of chronic beryllium disease.

Authors:  James A Snyder; Eugene Demchuk; Erin C McCanlies; Christine R Schuler; Kathleen Kreiss; Michael E Andrew; Bonnie L Frye; James S Ensey; Marcia L Stanton; Ainsley Weston
Journal:  J R Soc Interface       Date:  2008-07-06       Impact factor: 4.118

5.  A cell-based high-throughput screening assay system for inhibitor compounds of antigen presentation by HLA class II molecule.

Authors:  Nobuo Watanabe; Yusuke Suzuki; Takahisa Yonezu; Yuki Nakagawa; Takashi Shiina; Noriaki Hirayama; Sadaki Inokuchi; Shigeaki Inoue
Journal:  Sci Rep       Date:  2017-07-28       Impact factor: 4.379

6.  Dynamic Changes in the Intracellular Association of Selected Rab Small GTPases with MHC Class II and DM during Dendritic Cell Maturation.

Authors:  Gibrán Pérez-Montesinos; Orestes López-Ortega; Jessica Piedra-Reyes; Laura C Bonifaz; José Moreno
Journal:  Front Immunol       Date:  2017-03-27       Impact factor: 7.561

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.